However, TACE increases tumor-specific CD8 + T cell response and programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) expression, which provides an impetus for the exploration of immunotherapy after TACE [28]. The gene discussed is CD8A; the disease is neoplasm.